Ashling Wahner

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.

Switch ramucirumab/paclitaxel maintenance improved PFS and OS outcomes vs chemotherapy continuation in HER2-negative gastric or GEJ cancer.

The EMA's CHMP has recommended the conditional marketing authorization of odronextamab for relapsed/refractory FL and DLBCL.

Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.

Dostarlimab/chemotherapy/niraparib elicited favorable PFS outcomes across several subgroups in primary advanced or recurrent endometrial cancer.

An expanded indication for dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer is under EMA review.

Valemetostat tosilate has been approved by the Japan Ministry of Health, Labor and Welfare for the treatment of patients with relapsed/refractory PTCL.

Lauren E. Nye, MD, discusses the use of CDK4/6 inhibitors in HR-positive metastatic breast cancer and the evolution of ADCs in HER2-positive disease.

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Capivasertib/fulvestrant was approved in the EU for pretreated, ER-positive, HER2‑negative advanced cancer with 1 or more PIK3CA, AKT1, or PTEN alterations.

Aditya Bardia, MD, MPH, FASCO, discusses the evolving role of T-DXd for patients with HER2-positive advanced breast cancer.

Lauren E. Nye, MD, highlights reasons to look beyond CDK4/6 inhibitors when determining treatments for patients with hormone receptor–positive advanced breast cancer and more.

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

The combination of sonrotoclax and zanubrutinib had a tolerable safety profile and led to durable responses in relapsed/refractory CLL/SLL.

The CD7-targeted CAR T-cell therapy WU-CART-007 had a manageable safety profile and elicited preliminary efficacy signals in relapsed/refractory T-ALL/LBL.

Luspatercept elicited superior erythroid response rates and duration of RBC transfusion independence compared with epoetin alfa in lower-risk MDS.

The FDA granted fast track designation to IBI343 monotherapy for relapsed/refractory advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as future directions for rivoceranib plus camrelizumab in unresectable HCC.

UV1 added to pembrolizumab elicited sustained OS outcomes as frontline therapy in advanced, unresectable, or metastatic malignant melanoma.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

The FDA’s Medical Devices Advisory Committee recommends the approval of the Shield blood test for CRC screening in adults at average risk for CRC.

Treatment with CEE alone was associated with increased ovarian cancer incidence and mortality rates in postmenopausal women who had undergone hysterectomy.

Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma.

Inavolisib/palbociclib/fulvestrant was granted FDA granted breakthrough therapy designation for PIK3CA-mutated, HR-positive/HER2-negative breast cancer.

TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.